NIDA Translational Avant-Garde Award for Development of Medication to Treat Substance Use Disorders (UG3/UH3)

 

The purpose of this award is to support outstanding basic and/or clinical researchers with the vision and expertise to translate research discoveries into medications for the treatment of Substance Use Disorders (SUDs) stemming from tobacco, cannabis, cocaine, methamphetamine, heroin, or prescription opiate use.Eligible applicants must demonstrate the ability to develop molecules with the potential to treat SUDs and advance them in the drug development continuum. The ultimate goal of this FOA is to bring molecules closer to FDA approval.

Deleted 01/03/2016 (Archived.) RFA-DA-16-008 Agency: Department of Health and Human Services
Office: National Institutes of Health Cooperative Agreement 3 Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. 12/03/2015 This program does not have cost sharing or matching requirements. NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV
http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-16-008.html FBOWebmaster@OD.NIH.GOV $3,000,000.00 Awards up to $1,000,000.00